Related Experiment Video
Updated: Apr 15, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia
Marco Falcone1, Alessandro Russo2, Maddalena Giannella3
1Department of Public Health and Infectious Diseases, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy; Department of Emergency Medicine, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy.
Introduction:
The diffusion of multidrug-resistant (MDR) bacteria has created the need to identify risk factors for acquiring resistant pathogens in patients living in the community.
Objective:
To analyze clinical features of patients with community-onset pneumonia due to MDR pathogens, to evaluate performance of existing scoring tools and to develop a bedside risk score for an early identification of these patients in the Emergency Department.
Patients And Methods:
This was an open, observational, prospective study of consecutive patients with pneumonia, coming from the community, from January 2011 to January 2013. The new score was validated on an external cohort of 929 patients with pneumonia admitted in internal medicine departments participating at a multicenter prospective study in Spain.
Results:
A total of 900 patients were included in the study. The final logistic regression model consisted of four variables: 1) one risk factor for HCAP, 2) bilateral pulmonary infiltration, 3) the presence of pleural effusion, and 4) the severity of respiratory impairment calculated by use of PaO2/FiO2 ratio. A new risk score, the ARUC score, was developed; compared to Aliberti, Shorr, and Shindo scores, this point score system has a good discrimination performance (AUC 0.76, 95% CI 0.71-0.82) and calibration (Hosmer-Lemeshow, χ2 = 7.64; p = 0.469). The new score outperformed HCAP definition in predicting etiology due to MDR organism. The performance of this bedside score was confirmed in the validation cohort (AUC 0.68, 95% CI 0.60-0.77).
Conclusion:
Physicians working in ED should adopt simple risk scores, like ARUC score, to select the most appropriate antibiotic regimens. This individualized approach may help clinicians to identify those patients who need an empirical broad-spectrum antibiotic therapy.
Insights
A new risk score, the ARUC score, aids in identifying community-onset pneumonia caused by multidrug-resistant (MDR) bacteria. This score helps emergency department physicians select appropriate antibiotics for patients with MDR pathogens.
Area of Science:
- Infectious Diseases
- Pulmonology
- Clinical Microbiology
Background:
- The rise of multidrug-resistant (MDR) bacteria necessitates identifying risk factors for community-acquired resistant pathogens.
- Community-onset pneumonia (COP) poses a significant challenge due to the increasing prevalence of MDR organisms.
Purpose of the Study:
- To analyze clinical features of patients with COP due to MDR pathogens.
- To evaluate existing scoring tools for MDR pathogen identification in pneumonia.
- To develop a bedside risk score for early identification of MDR pneumonia in the Emergency Department (ED).
Main Methods:
- An observational, prospective study included 900 consecutive patients with community-acquired pneumonia.
- A logistic regression model identified key predictors for MDR pneumonia.
- The developed ARUC score was validated on an external cohort of 929 patients.
Main Results:
- The ARUC score incorporates risk factors for healthcare-associated pneumonia (HCAP), bilateral infiltrates, pleural effusion, and respiratory impairment (PaO2/FiO2 ratio).
- The ARUC score demonstrated good discrimination (AUC 0.76) and calibration, outperforming the HCAP definition in predicting MDR etiology.
- Validation confirmed the score's performance (AUC 0.68).
Conclusions:
- Emergency department physicians should utilize simple risk scores like the ARUC score.
- The ARUC score assists in selecting appropriate antibiotic regimens for MDR pneumonia.
- An individualized approach using risk scores can guide empirical broad-spectrum antibiotic therapy decisions.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
03:53Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Related Concept Videos
Mechanism of Antibiotic Resistance in MRSA
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Clinical Significance of Antibiotic Resistance
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment
Atypical Pneumonia